BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 75 filers reported holding BRIDGEBIO PHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $52,370 | -78.5% | 1,986 | -86.0% | 0.00% | -75.0% |
Q2 2023 | $243,534 | +338141.7% | 14,159 | +222.7% | 0.01% | +300.0% |
Q1 2023 | $72 | +44.0% | 4,388 | -32.3% | 0.00% | 0.0% |
Q4 2022 | $50 | -100.0% | 6,484 | -61.4% | 0.00% | -33.3% |
Q3 2022 | $167,000 | -44.0% | 16,795 | -48.8% | 0.00% | -57.1% |
Q2 2022 | $298,000 | +66.5% | 32,813 | +86.8% | 0.01% | +250.0% |
Q1 2022 | $179,000 | -34.9% | 17,566 | +6.4% | 0.00% | -60.0% |
Q4 2021 | $275,000 | -50.4% | 16,516 | +39.6% | 0.01% | -64.3% |
Q3 2021 | $554,000 | +69.9% | 11,832 | +121.3% | 0.01% | +75.0% |
Q2 2021 | $326,000 | -30.2% | 5,347 | -29.4% | 0.01% | 0.0% |
Q1 2021 | $467,000 | +165.3% | 7,579 | +206.3% | 0.01% | +60.0% |
Q4 2020 | $176,000 | +38.6% | 2,474 | -26.6% | 0.01% | +400.0% |
Q3 2020 | $127,000 | -83.6% | 3,371 | -85.8% | 0.00% | -96.9% |
Q2 2020 | $775,000 | +1939.5% | 23,776 | +2067.4% | 0.03% | +966.7% |
Q4 2019 | $38,000 | +280.0% | 1,097 | +136.9% | 0.00% | +200.0% |
Q3 2019 | $10,000 | – | 463 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |